Phase 3 Breast Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People of any gender aged 18 or older at the time of screening (or as defined by local guidelines)
• People who have been diagnosed with early-stage breast cancer that is ER-positive and HER2-negative, confirmed by a tissue sample, and where the cancer has been surgically removed with no signs of spread to other parts of the body
• People who have completed their main local treatment for the breast tumour, which may include surgery with or without radiation therapy, and may or may not have included chemotherapy before or after surgery
• People who are enrolled in the trial within 12 months of their definitive breast surgery
• People who have received up to 12 weeks of hormone-blocking (endocrine) therapy before being enrolled in the trial
• People whose general physical functioning is rated at a level indicating they are fully active or have only minor limitations (confirm with trial site)
• People with adequate functioning of their organs and bone marrow (confirm with trial site)

Who may not be able to join:

• People whose breast cancer cannot be surgically removed, has spread locally to an advanced degree, or has spread to other parts of the body
• People whose cancer completely disappeared after chemotherapy or other treatment given before surgery
• People with a history of another cancer, unless it was non-melanoma skin cancer, cervical carcinoma in situ, or a cancer considered very low risk by the doctor — or unless the person has been in complete remission with no treatment for at least 5 years before enrolment
• People with severe or poorly controlled serious illnesses that, in the doctor's judgement, would prevent safe participation in the trial
• People with a known weakened heart pumping function (below 50%) combined with moderate or severe heart failure symptoms
• People with a specific type of abnormal heart rhythm reading on an ECG above a certain threshold at screening (confirm with trial site)
• People currently using hormone therapies (not applied to the skin) for non-cancer-related reasons, such as contraception or hormone replacement
• People receiving any other cancer treatments not permitted by the trial, with the exception of certain bone-strengthening medications such as zoledronic acid or denosumab
• People who have previously been treated with camizestrant, fulvestrant, or certain other investigational drugs that target oestrogen receptors
• People who are currently pregnant or breastfeeding
• People with a known allergy or sensitivity to camizestrant or to drugs in a similar class — and, for people who are pre- or peri-menopausal or male, those with a known allergy or intolerance to a type of hormone-suppressing injection (LHRH agonist) that would prevent them from receiving any such treatment

Important: Always verify eligibility with the trial site directly before applying.